The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 24, 2026
Filed:
Jul. 07, 2022
Applicant:
Taris Biomedical Llc, Lexington, MA (US);
Inventors:
Assignee:
TARIS Biomedical LLC, Lexington, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/7068 (2006.01); A61K 45/06 (2006.01); A61M 31/00 (2006.01); A61P 13/10 (2006.01); A61P 35/00 (2006.01); C07H 19/06 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0034 (2013.01); A61K 9/0004 (2013.01); A61K 9/0024 (2013.01); A61K 9/0092 (2013.01); A61K 31/7068 (2013.01); A61K 45/06 (2013.01); A61M 31/002 (2013.01); A61P 13/10 (2018.01); A61P 35/00 (2018.01); C07H 19/06 (2013.01);
Abstract
Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).